Ibutilide (CCU)

CAUTION: High Administration Risk Rating	
Form	0.1mg/1mL (1mg/10mL ampoule)
Reconstitution	Already in solution **Further dilute before administration**
Compatibility & Stability	Glucose 5% Sodium Chloride 0.9%
Dose	Local practice is to use 1mg dose for all patients Ibutilide is given intravenously as the fumarate. The infusion should be stopped as soon as the arrhythmia is terminated. If the arrhythmia persists 10 minutes after completion of the infusion, a second infusion of the same dose may be given**.**
	REFER TO PROTOCOL FOR THE ADMINSTRATION OF IBUTILIDE (CORVERT®)
Administration	**IV infusion** 1mg diluted in 100mL of compatible diluent given over 10 minutes. (Local practice)
Monitoring	• Patients should be observed with continuous ECG monitoring during and for at least 5 hours following infusion (local practice). Longer monitoring is required if any arrhythmic activity is noted. • Electrolyte abnormalities should be corrected before treatment is started.
Additional Information	• Clear, colourless solution, discard if any discolouration or particulate matter. • Please refer to local Consultant regarding the pre-administration of magnesium sulphate (1g magnesium sulphate in 100mL sodium chloride over 10 minutes) prior to ibutilide administration. • Ibutilide is stocked in the CCU, Ward 3D and the Resuscitation room in the Emergency Dept.

Information provided relates to Corvert® Ibutilide manufactured by Pfizer.